Hemastatx brings innovation to patients with severe, underserved bleeding conditions. HMX-001 is a first-in-class anti-ADAMTS13 antibody targeting the root cause of severe bleeds in (rare) von Willebrand factor (VWF) disorders. Hemastatx is a KU Leuven spinoff and part of the BaseLaunch portfolio.
Products, services, technology
HMX-001 is a first-in-class anti-ADAMTS13 antibody designed to restore functional HMW-VWF and address major bleeds in (rare) VWF disorders, including congenital VWD and acquired VWS in mechanical circulatory support. Currently at preclinical stage, it presents a pipeline-in-a-product opportunity.
Cooperation possibilities
HMX-001 has demonstrated in vitro and in vivo proof of concept, is supported by a robust IP portfolio, and is currently in lead optimization. We are seeking follow-on funding to advance IND-enabling studies and clinical development, as well as potential licensing opportunities.
- http://www.hemastatx.com
- +32 495 99 79 64
- Send an email
- Kevin Hollevoet
